Arbutus Cash vs Short Term Debt Analysis
ABUS Stock | USD 3.46 0.01 0.29% |
Arbutus Biopharma financial indicator trend analysis is way more than just evaluating Arbutus Biopharma Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Arbutus Biopharma Corp is a good investment. Please check the relationship between Arbutus Biopharma Cash and its Short Term Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arbutus Biopharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
Cash vs Short Term Debt
Cash vs Short Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Arbutus Biopharma Corp Cash account and Short Term Debt. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Arbutus Biopharma's Cash and Short Term Debt is 0.43. Overlapping area represents the amount of variation of Cash that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of Arbutus Biopharma Corp, assuming nothing else is changed. The correlation between historical values of Arbutus Biopharma's Cash and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash of Arbutus Biopharma Corp are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Cash i.e., Arbutus Biopharma's Cash and Short Term Debt go up and down completely randomly.
Correlation Coefficient | 0.43 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Cash
Cash refers to the most liquid asset of Arbutus Biopharma Corp, which is listed under current asset account on Arbutus Biopharma Corp balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Arbutus Biopharma customers. The amounts must be unrestricted with restricted cash listed in a different Arbutus Biopharma account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.Short Term Debt
Most indicators from Arbutus Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Arbutus Biopharma Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arbutus Biopharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. At this time, Arbutus Biopharma's Issuance Of Capital Stock is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 2.32 in 2024, whereas Tax Provision is likely to drop 0.00 in 2024.
Arbutus Biopharma fundamental ratios Correlations
Click cells to compare fundamentals
Arbutus Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Arbutus Biopharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 105.5M | 137.1M | 204.5M | 195.4M | 144.4M | 124.4M | |
Other Current Liab | 253K | 5.8M | 7.3M | 20.5M | 9.9M | 10.4M | |
Total Current Liabilities | 7.8M | 9.5M | 11.2M | 32.9M | 22.5M | 23.6M | |
Total Stockholder Equity | 72.7M | 102.0M | 169.4M | 136.9M | 106.0M | 93.5M | |
Property Plant And Equipment Net | 11.4M | 9.3M | 8.1M | 6.8M | 6.1M | 4.8M | |
Net Debt | (28.4M) | (49.3M) | (106.7M) | (28.6M) | (17.6M) | (18.4M) | |
Retained Earnings | (970.1M) | (1.0B) | (1.1B) | (1.2B) | (1.3B) | (1.2B) | |
Cash | 31.8M | 52.3M | 109.3M | 30.8M | 26.3M | 39.9M | |
Non Current Assets Total | 11.7M | 9.4M | 43.8M | 44.3M | 12.4M | 11.8M | |
Non Currrent Assets Other | 293K | 44K | 61K | 103K | 92.7K | 88.1K | |
Cash And Short Term Investments | 90.8M | 123.3M | 155.3M | 146.9M | 126.0M | 73.6M | |
Net Receivables | 1.2M | 1.3M | 899K | 1.4M | 1.8M | 1.3M | |
Common Stock Total Equity | 898.5M | 985.9M | 1.3B | 1.3B | 1.5B | 1.6B | |
Common Stock Shares Outstanding | 57.1M | 75.8M | 106.2M | 150.9M | 166.0M | 174.3M | |
Short Term Investments | 59.0M | 71.0M | 46.0M | 116.1M | 99.7M | 104.7M | |
Liabilities And Stockholders Equity | 105.5M | 137.1M | 204.5M | 195.4M | 144.4M | 124.4M | |
Non Current Liabilities Total | 25.0M | 25.6M | 23.8M | 25.7M | 15.9M | 25.0M | |
Other Current Assets | 1.8M | 6.2M | 8.9M | 2.9M | 4.2M | 4.5M | |
Other Stockholder Equity | 55.2M | 60.8M | 65.5M | 72.4M | 81.3M | 85.3M | |
Total Liab | 32.8M | 35.1M | 35.0M | 58.6M | 38.4M | 31.0M | |
Property Plant And Equipment Gross | 11.4M | 9.3M | 8.1M | 6.8M | 18.0M | 18.9M | |
Total Current Assets | 93.8M | 127.7M | 160.7M | 151.1M | 132.0M | 76.6M | |
Common Stock | 898.5M | 985.9M | 1.3B | 1.3B | 1.3B | 1.4B | |
Other Liab | 21.9M | 23.0M | 21.6M | 23.9M | 27.5M | 18.6M | |
Net Tangible Assets | (64.5M) | (47.4M) | 169.4M | 136.9M | 157.4M | 165.2M | |
Accounts Payable | 2.4M | 3.0M | 3.2M | 3.5M | 3.2M | 2.5M | |
Retained Earnings Total Equity | (970.1M) | (1.0B) | (1.1B) | (1.2B) | (1.1B) | (1.0B) | |
Preferred Stock Total Equity | 49.8M | 126.1M | 137.3M | 149.4M | 171.8M | 180.4M | |
Accumulated Other Comprehensive Income | (48.2M) | (48.2M) | (48.3M) | (50.5M) | (48.4M) | (46.0M) | |
Property Plant Equipment | 8.7M | 6.9M | 6.0M | 5.1M | 5.8M | 4.5M | |
Capital Surpluse | 55.2M | 60.8M | 65.5M | 72.4M | 83.3M | 53.5M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arbutus Stock Analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.